BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shahverdi M, Hajiasgharzadeh K, Sorkhabi AD, Jafarlou M, Shojaee M, Jalili Tabrizi N, Alizadeh N, Santarpia M, Brunetti O, Safarpour H, Silvestris N, Baradaran B. The regulatory role of autophagy-related miRNAs in lung cancer drug resistance. Biomedicine & Pharmacotherapy 2022;148:112735. [DOI: 10.1016/j.biopha.2022.112735] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Shadbad MA, Ghorbaninezhad F, Hassanian H, Ahangar NK, Hosseinkhani N, Derakhshani A, Shekari N, Brunetti O, Silvestris N, Baradaran B. A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1027758] [Reference Citation Analysis]
2 Yan H, Tang S, Tang S, Zhang J, Guo H, Qin C, Hu H, Zhong C, Yang L, Zhu Y, Zhou H. miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.949566] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Jiang YF, Wei SN, Geng N, Qin WW, He X, Wang XH, Qi YP, Song S, Wang P. Evaluation of circulating small extracellular vesicle-derived miRNAs as diagnostic biomarkers for differentiating between different pathological types of early lung cancer. Sci Rep 2022;12:17201. [PMID: 36229645 DOI: 10.1038/s41598-022-22194-0] [Reference Citation Analysis]
4 Keshavarz A, Salehi A, Khosravi S, Shariati Y, Nasrabadi N, Kahrizi MS, Maghsoodi S, Mardi A, Azizi R, Jamali S, Fotovat F. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. Stem Cell Res Ther 2022;13. [DOI: 10.1186/s13287-022-03163-w] [Reference Citation Analysis]
5 Liu P, Chen C, Ger L, Tsai W, Tseng H, Lee C, Yang W, Shu C. MAP3K11 facilitates autophagy activity and is correlated with malignancy of oral squamous cell carcinoma. Journal Cellular Physiology. [DOI: 10.1002/jcp.30881] [Reference Citation Analysis]
6 Zhou X, Ao X, Jia Z, Li Y, Kuang S, Du C, Zhang J, Wang J, Liu Y. Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications. Front Oncol 2022;12:951864. [PMID: 36059609 DOI: 10.3389/fonc.2022.951864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 Doghish AS, Ismail A, Elrebehy MA, Elbadry AM, Mahmoud HH, Farouk SM, Serea GAA, Elghany RAA, El-halwany KK, Alsawah AO, Dewidar HI, El-mahdy HA. A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: A focus on signaling pathways interplay. Pathology - Research and Practice 2022;237:154053. [DOI: 10.1016/j.prp.2022.154053] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Daei Sorkhabi A, Sarkesh A, Saeedi H, Marofi F, Ghaebi M, Silvestris N, Baradaran B, Brunetti O. The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme. Front Oncol 2022;12:818447. [PMID: 35515137 DOI: 10.3389/fonc.2022.818447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Shomali N, Suliman Maashi M, Baradaran B, Daei Sorkhabi A, Sarkesh A, Mohammadi H, Hemmatzadeh M, Marofi F, Sandoghchian Shotorbani S, Jarahian M. Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies. Front Immunol 2022;13:839945. [PMID: 35309327 DOI: 10.3389/fimmu.2022.839945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
10 Mardi A, Shirokova AV, Mohammed RN, Keshavarz A, Zekiy AO, Thangavelu L, Mohamad TAM, Marofi F, Shomali N, Zamani A, Akbari M. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. Cancer Cell Int 2022;22:168. [PMID: 35488303 DOI: 10.1186/s12935-022-02585-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]